Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laquinimod in primary progressive multiple sclerosis
NL-OMON41832Phase 2Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of laquinimod in primary progressive multiple sclerosis (PPMS) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Percentage brain volume change. Started Jun 2015; status: active, not recruiting.
02
Drugs
laquinimod
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NL-OMON41832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41832.